AUSTIN,
Texas, July 30, 2024 /PRNewswire/ -- Aileron
Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical
company advancing a novel pipeline of first-in-class medicines to
address significant unmet medical needs in orphan pulmonary and
fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief
Executive Officer, will present at the Canaccord Genuity 44th
Annual Growth Conference on Tuesday, August
13, 2024 at 4:00 p.m. EDT in
Boston, MA.
A live webcast of the event can be accessed at
https://investors.aileronrx.com/events-presentations/investor-events.
A replay of the webcast will be available for 90 days following the
presentation.
About Aileron Therapeutics
Aileron Therapeutics, Inc. is a biopharmaceutical company
advancing a novel pipeline of first-in-class medicines to address
significant unmet medical needs in orphan pulmonary and fibrosis
indications. Aileron's lead product candidate, LTI-03, is a novel,
synthetic peptide with a dual mechanism targeting alveolar
epithelial cell survival as well as inhibition of profibrotic
signaling. Currently, LTI-03 is being evaluated in a Phase
1b clinical trial for the treatment
of idiopathic pulmonary fibrosis. Aileron's second product
candidate, LTI-01, is a proenzyme that has completed Phase
1b and Phase 2a clinical trials for
the treatment of loculated pleural effusions. LTI-01 has received
Orphan Drug Designation in the US and EU and Fast Track Designation
in the US.
Investor Relations & Media Contact:
Argot
Partners
aileron@argotpartners.com
212-600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aileron-therapeutics-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-302208743.html
SOURCE Aileron Therapeutics, Inc.